Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Fidelity Growth Partner Asia's Norman Chen On Being An Active Investor In China: An Interview With PharmAsia News (Part 2 of 2)

This article was originally published in PharmAsia News

Executive Summary

Fidelity Growth Partners Asia has made its name on several blockbuster investments in China. In the IT sector, Fidelity invested in Alibaba, China's leading e-commerce company. In healthcare, Fidelity was an early investor in China's leading CRO WuXi AppTec Inc. and remains one of its largest shareholders.

You may also be interested in...



Fidelity Growth Partner Asia's Norman Chen On Being An Active Investor In China: An Interview With PharmAsia News (Part 1 of 2)

Fidelity Growth Partners Asia has made its name on several blockbuster investments in China. In the IT sector, Fidelity invested in Alibaba, China's leading e-commerce company. In healthcare, Fidelity was an early investor in China's leading CRO WuXi AppTec Inc. and remains one of its largest shareholders.

Big Pharma Takes Another Haircut As China Slashes Drug Prices In Two Largest Therapy Fields

SHANGHAI - While Beijing is hosting China's National People's Congress this week to discuss and design its next Five-Year Plan, China's powerful National Development and Reform Commission announced another round of price cuts on antibiotics and cardiovascular drugs with an average price reduction of 21%, less than the rumored 30-40% cuts, but still a blow to Big Pharma

China's State FDA Gets WHO Nod For Vaccine Regulatory System; Opens Global Market For Chinese Vaccine Makers

SHANGHAI - China's State FDA now complies with international standards for vaccine regulation and Chinese vaccine makers are eligible to apply for World Health Organization prequalification of vaccine products, WHO announced March 1, the same day that China implemented its newly revised good manufacturing practices (GMP) guidelines

Related Content

UsernamePublicRestriction

Register

LL1134478

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel